BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26590832)

  • 1. Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective data review.
    Al-Khalil S; Boothe D; Durdin T; Sunkara S; Watkins P; Yang S; Haynes A; de Riese W
    Int Urol Nephrol; 2016 Jan; 48(1):91-7. PubMed ID: 26590832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
    Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
    Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of prostate-specific antigen density in predicting prostate cancer when serum prostate-specific antigen levels are less than 10 ng/ml.
    Akdas A; Tarcan T; Türkeri L; Cevik I; Biren T; Ilker Y
    Eur Urol; 1996; 29(2):189-92. PubMed ID: 8647145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
    Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
    Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
    Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
    J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria.
    Udeh EI; Nnabugwu II; Ozoemena FO; Ugwumba FO; Aderibigbe AS; Ohayi SR; Echetabu KN
    World J Surg Oncol; 2016 Jun; 14(1):174. PubMed ID: 27356753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S; Cakar B; Conkbayir I; Hekimoglu B
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen density: correlation with histological diagnosis of prostate cancer, benign prostatic hyperplasia and prostatitis.
    van Iersel MP; Witjes WP; de la Rosette JJ; Oosterhof GO
    Br J Urol; 1995 Jul; 76(1):47-53. PubMed ID: 7544204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and prostate-specific antigen density.
    Benson MC; McMahon DJ; Cooner WH; Olsson CA
    World J Urol; 1993; 11(4):206-13. PubMed ID: 7508785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
    Zackrisson B; Aus G; Lilja H; Lodding P; Pihl CG; Hugosson J
    Eur Urol; 2003 Apr; 43(4):327-32. PubMed ID: 12667711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of patients with diseases of the prostate using prostate-specific antigen density.
    Wolff JM; Boeckmann W; Effert PJ; Handt S; Jakse G
    Br J Urol; 1995 Jul; 76(1):41-6. PubMed ID: 7544203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
    Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
    Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer].
    Iwaki H; Kajita Y; Shimizu Y; Yamauchi T
    Hinyokika Kiyo; 2001 Mar; 47(3):169-74. PubMed ID: 11329957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective comparison between transrectal and transperineal prostate biopsy in the detection of prostate cancer.
    Di Franco CA; Jallous H; Porru D; Giliberto GL; Cebrelli T; Tinelli C; Rovereto B
    Arch Ital Urol Androl; 2017 Mar; 89(1):55-59. PubMed ID: 28403597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men.
    Sheikh M; Al-Saeed O; Kehinde EO; Sinan T; Anim JT; Ali Y
    Int Urol Nephrol; 2005; 37(4):721-6. PubMed ID: 16362587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of prostate volume measurement using transabdominal ultrasonography for the improvement of prostate-speci fi c antigen-based cancer detection.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    Int J Urol; 2005 Oct; 12(10):881-5. PubMed ID: 16323981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy.
    Bare R; Hart L; McCullough DL
    Urology; 1994 Feb; 43(2):191-6. PubMed ID: 7509526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of free-to-total prostate specific antigen (F/T PSA), prostate specific antigen density (PSAD) and (F/T)/PSAD sensitivity on reduction of unnecessary prostate biopsies for patients with PSA in gray zone.
    Milkovic B; Dzamic Z; Pejcic T; Kajmakovic B; Nikolic D; Cirovic D; Knezevic T; Dzamic D; Hadzi-Djokic J
    Ann Ital Chir; 2014; 85(5):448-53. PubMed ID: 25599711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.